RVMD

Revolution Medicines, Inc.

HealthcareBiotechnologyUSUSDPeers →

$169.51

+1.45%LiveJun 23, 2026

AI Brief

Market cap

$36.04B

52w range

34.00 – 171.21

P / E

—

EPS

—

Volume

3.12M

Revenue · FY

—

Overview Fundamentals Valuation Market Narrative & AI

Explain this page

Arphra AIPlain-English read on Revolution Medicines, Inc.’s valuation

decile 9 · 0% factors bull

News pulse · 14d

3 storiesPositive +0.90All news →

06-11today

AI Issuer Brief

Arphra AI

Loading cached brief…

Price

DB · prices_daily

1M 6M 1Y 5Y

Last

$162.99

Change

+307.17%

Period high

$163.68

Period low

$34.70

Period start

$40.032025-06-24

Through 2026-06-18

Fair value

Football field →

Weighted blend

—

— vs spot

Recommendation

n/a

0 of 0 methods

Method spread

0bull0bear

±5% threshold

Analyst PT consensus: $165.75 (-2.22%)

Candlestick · 1Y

Open in chart workstation →

RVMD

162.99+307.17%

H 166.50L 34.00MA50 146.50MA200 95.18Avg vol 2.8M

Price change · trailing returns

Live

1D	5D	1M	3M	6M	YTD	1Y	3Y	5Y	10Y	Max
+2.23%	+4.43%	+11.84%	+77.46%	+108.78%	+112.82%	+323.46%	+581.58%	+418.38%	+486.54%	+486.54%

Insider · 30d

History →

Bought

0 txns

Sold

0 txns

Net flow

+$0

Aftermarket

Live

Jun 24, 09:01 AM

Last trade

$170.66

120 sh

Bid

$167.00

4 sh

Ask

$173.82

1 sh

Spread

$6.820

Recent quarters

All financials →

Period	Revenue	Net income	EPS

Sector & industry today

Live

Sectors

Real Estate
+1.01%
Consumer Cyclical
+0.94%
Energy
+0.84%
Consumer Defensive
+0.82%
Financial Services
+0.23%
Basic Materials
-0.11%
Healthcare
-0.18%
Communication Services
-0.18%
Industrials
-0.47%
Technology
-0.85%
Utilities
-1.03%

Top industries (issuer's industry highlighted)

Biotechnology
+3.28%
Software - Services
+9.60%
Broadcasting
+8.34%
Travel Services
+7.87%
Computer Hardware
+4.56%
Oil & Gas Energy
-3.54%
Electrical Equipment & Parts
-3.26%
Semiconductors
-2.12%
Communication Equipment
+2.06%
REIT - Healthcare Facilities
+2.01%
Drug Manufacturers - Specialty & Generic
+1.99%
Consulting Services
-1.97%

Analyst view

Consensus target

—

No price-target data returned for this ticker.

Recent actions

0 ↑0 ↓0 hold

No recent grade actions.

News

DB · news_items

Recent analyst activity

11 latest

Jun 22, 2026GradeOutperform → OutperformRBC Capital Reiterates Outperform Rating on Revolution (RVMD)RBC Capital
Jun 09, 2026PT$175.00UBS Reiterates Buy Rating on Revolution (RVMD) Following Trial Data ReleaseUBS
Jun 09, 2026GradeBuy → BuyUBS Reiterates Buy Rating on Revolution (RVMD) Following Trial Data ReleaseUBS
Jun 02, 2026PT$182.00Revolution (RVMD) PT Raised to $182 at RBC CapitalRBC Capital
Jun 02, 2026GradeOutperform → OutperformRevolution (RVMD) PT Raised to $182 at RBC CapitalRBC Capital
Jun 01, 2026PT$195.00Revolution Medicines price target raised to $195 from $169 at H.C. WainwrightH.C. Wainwright
Jun 01, 2026GradeBuy → BuyRevolution Medicines price target raised to $195 from $169 at H.C. WainwrightH.C. Wainwright
Jun 01, 2026GradeOutperform → OutperformWedbush reiterates Outperform on Revolution Medicines after ASCO dataWedbush
Jun 01, 2026GradeBuy → BuyTD Cowen Reiterates Buy Rating and Top Pick on Revolution (RVMD)Cowen & Co.
Jun 01, 2026GradeOutperform → OutperformRevolution Medicines price target raised to $195 from $165 at OppenheimerOppenheimer
Jun 01, 2026PT$195.00Revolution Medicines price target raised to $195 from $165 at OppenheimerOppenheimer

Financial scores

DBJun 23, 2026

Altman Z

24.81

Safe

≥ 3.0 safe · 1.81–3.0 grey · < 1.81 distress

Piotroski F

1/9

Weak

≥ 7 strong · 4–6 average · < 4 weak

Peers

No peer list available for RVMD.

Total assets

—

Total debt

—

Cash & equiv

—

Operating CF

—

Free cash flow

—

Buybacks

—

Recent insiders

All →

Insider	Action	Shares	Value	Date
No open-market insider activity in the recent window.

Income statement · annual

Open Financials →

Period	Revenue	Op income	Net income	EPS	Net margin